Feed VERU
VE

Veru Inc.

VERU · NASDAQ

$2.50 +2.25% (+$0.06)
1M -3.47%
Market Cap $40.1M
P/E Ratio -
Div. Yield -
ROE 45.89%

Bulios Fair Price

$3.03

21.2% upside

Trenutna cena

$2.5

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica VERU trenutno podcenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
1/9
Valuation
100 /100
Cheap
P/B 1.41x
PEG N/A
P/E N/A
Growth
0 /100
Declining
Book val. growth 39.50%
FCF growth N/A
EPS growth N/A
Profitability
-
N/A
Op. margin N/A
Gross margin N/A
FCF margin N/A
Quality
0 /100
Poor
ROA 36.75%
ROIC 60.64%
Asset turnover 0.00x
Debt
100 /100
Low
Current ratio 4.42x
Debt/Equity 0.09x
Debt/Assets N/A
Stability
27 /100
Unstable
EPS volatility 42.39%
Beta -1.16x
Profitable years 0

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o VERU
Online

O podjetju

Veru Inc. (VERU) is an American pharmaceutical company focused on research, development, and commercialization of therapeutic products in the fields of urology and oncology. The company specializes in the treatment of oncological diseases, including prostate, breast, and other malignancies. Veru is also involved in the treatment of sexually transmitted infections and other urological indications. The company is dedicated to innovative therapeutic approaches and researching new drugs to improve the quality of life for patients and provide them with new treatment options. Veru Inc. has a strong foundation in medical research and development and collaborates with renowned experts in the fields of oncology and urology. Investing in Veru Inc. (VERU) shares may represent an attractive choice for investors who follow the pharmaceutical sector and seek a company with potential in innovative treatments for oncological and urological diseases.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Mitchell S. Steiner

Employees

20

Headquarters

Miami

Prihajajoči dogodki

26 NOV.

Earnings

Upcoming earnings report

64d
16 DEC.

Earnings

Upcoming earnings report

84d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.